Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Atomoxetine Hydrochloride”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05350215
What this trial is testing

Atomoxetine and DAW2022 on OSA Severity

Who this might be right for
Obstructive Sleep Apnea
Brigham and Women's Hospital 18
Not applicableStudy completedNCT04132557
What this trial is testing

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Who this might be right for
Attention Deficit Disorder With Hyperactivity
Janssen Research & Development, LLC 430,000
Post-approval studies (Phase 4)Study completedNCT00190931
What this trial is testing

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

Who this might be right for
Attention Deficit Disorder With Hyperactivity
Eli Lilly and Company 400
Post-approval studies (Phase 4)Study completedNCT00585910
What this trial is testing

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

Who this might be right for
ADHDAttention Deficit Hyperactivity Disorder
Massachusetts General Hospital 94
Large-scale testing (Phase 3)Study completedNCT00320528
What this trial is testing

Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Who this might be right for
Attention Deficit Disorder With Hyperactivity
Eli Lilly and Company 269
Post-approval studies (Phase 4)UnknownNCT03781765
What this trial is testing

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Who this might be right for
ADHDAttention Deficit Hyperactivity Disorder
Icahn School of Medicine at Mount Sinai 44
Post-approval studies (Phase 4)Study completedNCT00181766
What this trial is testing

Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

Who this might be right for
ADHD NOS
Massachusetts General Hospital 45
Large-scale testing (Phase 3)Study completedNCT00191737
What this trial is testing

An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

Who this might be right for
Attention Deficit Hyperactivity Disorder
Eli Lilly and Company 147
Testing effectiveness (Phase 2)Study completedNCT00485628
What this trial is testing

Safety Study in Outpatient Japanese Children With ADHD

Who this might be right for
Attention Deficit Hyperactivity Disorder
Eli Lilly and Company 37
Large-scale testing (Phase 3)Study completedNCT00498173
What this trial is testing

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

Who this might be right for
Autism
Massachusetts General Hospital 60
Large-scale testing (Phase 3)Study completedNCT00486083
What this trial is testing

Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD

Who this might be right for
Attention Deficit Hyperactivity Disorder
Eli Lilly and Company 330
Testing effectiveness (Phase 2)Study completedNCT00607568
What this trial is testing

Atomoxetine Effects in Humans

Who this might be right for
Physiological Stress
Yale University 10
Large-scale testing (Phase 3)Study completedNCT01106430
What this trial is testing

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Who this might be right for
Attention-Deficit/Hyperactivity Disorder
Shire 267
Not applicableLooking for participantsNCT07239791
What this trial is testing

Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE)

Who this might be right for
Role of the Noradrenergic System in the Regulation of Learning DynamicsNo Disease or Condition is Being Studied
Centre Hospitalier St Anne 160
Very early researchStudy completedNCT02879136
What this trial is testing

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

Who this might be right for
Parkinson's Disease, Idiopathic
Hubert Fernandez 23
Testing effectiveness (Phase 2)Study completedNCT05101122
What this trial is testing

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

Who this might be right for
Obstructive Sleep Apnea
Apnimed 15
Large-scale testing (Phase 3)Study completedNCT05813275
What this trial is testing

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

Who this might be right for
OSA
Apnimed 646
Post-approval studies (Phase 4)Study completedNCT01065259
What this trial is testing

Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children

Who this might be right for
Attention Deficit Hyperactivity Disorder
Peking University 262
Testing effectiveness (Phase 2)Study completedNCT01738191
What this trial is testing

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

Who this might be right for
Parkinson's DiseaseCognitive Impairment
Medical University of South Carolina 30
Early research (Phase 1)Study completedNCT01177943
What this trial is testing

A Bioequivalence (BE) Study in Healthy Subjects

Who this might be right for
Attention Deficit Hyperactivity Disorder
Eli Lilly and Company 42
Next Page